Reviewed 18 May 2026

Example research study

Targeted Protein Degradation in 2026: PROTACs, Molecular Glues, and the Clinical Evidence So Far

Targeted protein degradation has moved from proof-of-concept to Phase III clinical trials, with Vepdegestrant (ARV-471) approaching NDA submission for ER+ breast cancer and Iberdomide achieving 100% ORR in multiple myeloma combination regimens. This review traces the mechanistic logic, clinical milestones, resistance pathways, and design challenges across 20 verified PubMed sources.

TL;DR Targeted protein degradation (TPD) uses small molecules—PROTACs and molecular glues—to hijack the ubiquitin-proteasome system and destroy disease-driving proteins rather than merely blocking them. Lead compounds are now in Phase II/III trials for breast cancer (Vepdegestrant), prostate cancer (Bavdegalutamide), and multiple myeloma (Iberdomide). Resistance emerges through MDR1 efflux pump upregulation, E3 ligase mutations, and target-site alterations. Key design challenges include the high molecular weight of PROTACs (700–1200 Da), the Hook Effect at saturating concentrations, and the lack of rational discovery methods for molecular glues. Expansion into neurodegeneration and autoimmune disease depends on identifying tissue-specific E3 ligases and achieving CNS penetration.

From Occupancy-Driven to Event-Driven Pharmacology in Drug Design

Conventional small-molecule drugs operate through occupancy-driven pharmacology: they bind a target’s active site and block its enzymatic function for as long as the drug concentration exceeds a therapeutic threshold. Targeted protein degradation inverts this logic. A degrader molecule acts catalytically—it induces the destruction of the target protein via the cell’s own ubiquitin-proteasome system (UPS) and is then recycled to repeat the process (PMID: 26075522, PMID: 35042991).

This event-driven mechanism confers several advantages. A single PROTAC molecule can eliminate hundreds of copies of its target, enabling sub-stoichiometric dosing. Because the entire protein is destroyed rather than merely inhibited, non-enzymatic functions—scaffolding interactions, allosteric signalling, protein-protein interactions—are abolished as well. For targets like transcription factors and intrinsically disordered proteins that lack conventional druggable pockets, degradation represents the only viable pharmacological strategy (PMID: 40266852, PMID: 35042991).

PROTACs, Molecular Glues, and Emerging Degrader Architectures

The TPD landscape is defined by two clinically validated molecular architectures and several emerging platforms that expand the addressable proteome.

PROTACs (Proteolysis-Targeting Chimeras) are heterobifunctional molecules composed of three elements: a ligand that binds the protein of interest (POI), a ligand that recruits an E3 ubiquitin ligase (most commonly CRBN or VHL), and a chemical linker that bridges the two. The PROTAC induces a ternary complex (POI–PROTAC–E3) that positions the POI for polyubiquitination by an E2 conjugating enzyme; the tagged protein is then recognised and degraded by the 26S proteasome (PMID: 36046485, PMID: 41362117).

Molecular glue degraders are monovalent small molecules without a formal linker. They bind to the surface of an E3 ligase—typically Cereblon (CRBN)—and reshape its geometry to create a neo-interaction with a substrate that the ligase would not naturally recognise. The thalidomide derivatives (IMiDs) such as lenalidomide recruit the transcription factors IKZF1 and IKZF3 to CRBN for degradation; this mechanism was discovered retrospectively and remains difficult to engineer rationally (PMID: 39759140, PMID: 41683435).

Emerging platforms extend degradation beyond the proteasome. LYTACs (lysosome-targeting chimeras) bridge extracellular or membrane-bound proteins to lysosome-shuttling receptors such as CI-M6PR, redirecting targets into the endolysosomal pathway (PMID: 32728216). AUTOTACs (autophagy-targeting chimeras) exploit selective autophagy to clear large protein aggregates that cannot be threaded into the narrow proteasome barrel (PMID: 40109019).

Comparison of major TPD modalities

Feature	PROTACs	Molecular Glues	LYTACs
Architecture	Heterobifunctional (POI ligand + linker + E3 ligand)	Monovalent; reshapes E3 surface	Bifunctional; targets extracellular/membrane proteins to lysosome
Molecular weight	700–1200 Da (beyond Rule of Five)	300–500 Da (drug-like)	Variable; often antibody-conjugated
Rational design	Yes — modular ligand + linker optimisation	Largely serendipitous; structure-guided discovery emerging	Modular; receptor-ligand pairing
Degradation pathway	Ubiquitin-proteasome system	Ubiquitin-proteasome system	Endolysosomal pathway
Clinical stage (2026)	Phase III (Vepdegestrant, ARV-110)	Phase III (Iberdomide); Phase I (CC-90009)	Preclinical
Target space	Intracellular proteins with a ligandable surface	Neo-substrates of CRBN/DDB1	Extracellular and membrane-bound proteins

Clinical Milestones: Oncology Leads and Non-Oncology Expansion

Several TPD therapeutics have produced quantitative efficacy data in human trials, establishing a clinical evidence base that extends beyond oncology into inflammation and neurodegeneration.

Vepdegestrant (ARV-471) is an oral estrogen receptor (ER) PROTAC for ER+/HER2− advanced breast cancer. Phase I/II data confirmed robust ER degradation superior to the standard-of-care fulvestrant. Phase III results reported at ASCO 2025 demonstrated a >40% reduction in disease progression risk in patients with ESR1-mutated tumours, and an NDA submission is anticipated (PMID: 39585895, PMID: 35042991).

Bavdegalutamide (ARV-110) is the first-in-class oral androgen receptor (AR) PROTAC for metastatic castration-resistant prostate cancer (mCRPC). Phase I data showed dose-dependent AR degradation and PSA reductions in heavily pretreated patients (PMID: 39670468, PMID: 35042991).

Iberdomide (CC-220) is a Cereblon E3 ligase modulator (CELMoD) molecular glue. In combination with bortezomib and dexamethasone for newly diagnosed multiple myeloma, it achieved a 100% overall response rate (ORR), with 87.5% of patients reaching very good partial response or better and 43% achieving minimal residual disease negativity (PMID: 39759140).

CC-90009 is the first clinical-grade GSPT1-selective molecular glue, demonstrating dose-dependent GSPT1 degradation in relapsed/refractory acute myeloid leukaemia (AML) in Phase Ib trials combined with venetoclax (PMID: 33197925, PMID: 39759140).

Ternary Complex Stability and Degradation Efficiency

The pharmacological potency of a degrader is not simply a function of its binding affinity for the POI. It depends on the stability and cooperativity of the ternary complex formed between the POI, the degrader, and the E3 ligase.

Positive cooperativity (α > 1) arises when protein-protein interactions (PPIs) between the POI and the E3 ligase stabilise the complex beyond the sum of the individual binary affinities. This cooperativity is a stronger predictor of degradation potency (DC₅₀) than POI binding affinity alone (PMID: 37443112). The linker plays a decisive role: its length, flexibility, and attachment geometry determine whether the POI’s surface-exposed lysines fall within the “ubiquitination zone” accessible to the E2-ubiquitin conjugate (PMID: 36046485, PMID: 41362117).

A second determinant is the rate of degradation relative to the rate of de novo protein synthesis. Sustained target knockdown occurs only when induced degradation significantly exceeds resynthesis (PMID: 38724444). This kinetic parameter is target-specific: proteins with long half-lives and low transcriptional activity are more amenable to durable depletion than rapidly resynthesised ones.

The Hook Effect: When Higher Doses Reduce Degradation Efficacy

A distinctive pharmacological liability of bifunctional degraders is the Hook Effect. At concentrations above the optimal range, excess degrader molecules saturate either the POI or the E3 ligase independently, forming non-productive binary complexes (degrader–POI or degrader–E3) that compete with the functional ternary complex. The result is a bell-shaped dose-response curve where degradation efficiency peaks at an intermediate concentration and then declines (PMID: 37443112, PMID: 41362117).

This phenomenon has practical implications for clinical dosing. Unlike conventional inhibitors, where higher plasma concentrations generally increase efficacy, PROTAC dosing must be titrated to maintain the concentration window that maximises ternary complex formation. Linker chemistry that enhances cooperativity can shift the hook-effect threshold to higher concentrations, widening the therapeutic window (PMID: 36046485).

Acquired Resistance to Protein Degradation Therapies

Resistance to TPD mirrors the selective pressures observed with conventional inhibitors but introduces additional failure modes unique to the dependence on E3 ligase machinery.

MDR1 efflux pump upregulation. Due to their large, hydrophobic structures, PROTACs are substrates for the multidrug resistance protein 1 (MDR1, encoded by ABCB1). Chronic exposure to BET-protein and CDK9 degraders triggers MDR1 upregulation via ABCB1 gene amplification and promoter hypomethylation, reducing intracellular drug accumulation. MDR1 inhibitors such as tariquidar can re-sensitise resistant cells (PMID: 36041010).

E3 ligase genomic alterations. Mutations in CRBN, VHL, or accessory Cullin-RING ligase subunits (e.g., CUL2) can abolish ternary complex formation. In multiple myeloma, specific CRBN mutations confer resistance to IMiD-based glues. Cells resistant to CRBN-based degraders may remain sensitive to compounds recruiting alternative ligases such as DCAF1 (PMID: 41683435, PMID: 38322348).

Target protein mutations. Point mutations at the POI–E3 binding interface destabilise the ternary complex without necessarily affecting inhibitor binding. CDK12 mutations, for example, confer resistance to the molecular glue BSJ-4-116 (PMID: 41683435). Increased deubiquitinase (DUB) activity can also rescue tagged proteins before proteasomal degradation (PMID: 41362117).

Physicochemical and Pharmacokinetic Design Challenges for Degraders

Most PROTACs reside in the “beyond Rule of Five” (bRo5) chemical space, with molecular weights of 700–1200 Da and high polar surface areas. This translates to poor oral bioavailability and limited membrane permeability—the defining translational bottleneck for the modality (PMID: 40284496, PMID: 35042991).

Delivery strategies under investigation include amorphous solid dispersions, lipid nanoparticles, and exosome-based carriers. While these approaches improve exposure in preclinical models, robust clinical pharmacokinetic data are still sparse (PMID: 40284496, PMID: 40324952).

For CNS indications—targeting Tau, α-synuclein, or mutant huntingtin—the blood-brain barrier (BBB) presents an additional obstacle. The size and polarity of PROTACs are generally incompatible with passive BBB diffusion. Peptide-based degraders (pepTACs) and nanoparticle formulations are being explored as alternatives, but no CNS-targeted degrader has reached clinical evaluation to date (PMID: 38685916, PMID: 40109019).

Molecular glues circumvent many of these problems by virtue of their smaller size (300–500 Da) and conventional drug-like properties. However, their discovery relies heavily on serendipity: there is no systematic methodology to predict which surface modification of an E3 ligase will create productive neo-substrate interactions (PMID: 39759140, PMID: 37437222).

Who Benefits from Targeted Protein Degradation Research

Frequently Asked Questions About Protein Degradation Therapeutics

What is the difference between a PROTAC and a molecular glue degrader?

PROTACs are heterobifunctional molecules with separate ligands for the target protein and the E3 ligase connected by a chemical linker. Molecular glues are smaller monovalent compounds that reshape the surface of an E3 ligase to create a novel binding interface with a neo-substrate. PROTACs are rationally designable; molecular glue discovery remains largely serendipitous (PMID: 36046485, PMID: 39759140).

Which targeted protein degraders have reached late-stage clinical trials?

Vepdegestrant (ARV-471), an ER degrader for ER+/HER2− breast cancer, is the most advanced PROTAC with Phase III data. Bavdegalutamide (ARV-110) targets the AR in mCRPC. The molecular glue Iberdomide (CC-220) has shown a 100% ORR in combination regimens for newly diagnosed multiple myeloma (PMID: 35042991, PMID: 39759140).

What is the Hook Effect in protein degradation?

The Hook Effect is a concentration-dependent paradox where excessive degrader concentrations saturate either the target protein or the E3 ligase, forming non-productive binary complexes instead of the functional ternary complex required for degradation. This produces a bell-shaped dose-response curve (PMID: 37443112, PMID: 41362117).

How do cancer cells develop resistance to PROTACs?

Resistance arises through three main routes: upregulation of the MDR1 (ABCB1) efflux pump that expels PROTACs from the cell; genomic alterations in E3 ligase components such as CRBN or VHL that prevent ternary complex formation; and mutations at the target–ligase binding interface that destabilise the degradation complex (PMID: 36041010, PMID: 41683435).

Can PROTACs target proteins outside the cell?

Standard PROTACs and molecular glues target intracellular proteins via the UPS. For extracellular and membrane-bound proteins, emerging modalities like LYTACs (lysosome-targeting chimeras) redirect targets to the endolysosomal pathway for degradation, expanding the addressable proteome beyond the proteasome (PMID: 32728216, PMID: 40324952).

Why is targeted protein degradation expanding into neurodegenerative diseases?

TPD can eliminate toxic protein aggregates such as Tau, α-synuclein, and mutant huntingtin that lack druggable enzymatic pockets. These scaffolding proteins resist conventional inhibition because their pathogenic role is structural, not catalytic. The primary hurdle is delivering high-molecular-weight degraders across the blood-brain barrier (PMID: 38685916, PMID: 40109019).

How does BioSkepsis help researchers study targeted protein degradation?

BioSkepsis synthesises the TPD literature with PMID-grounded citations, verifies each claim against the primary source, and flags contradictions or coverage gaps. Researchers can trace every assertion back to a specific paper rather than relying on unverified summaries from general-purpose AI tools.

Synthesise the Protein Degradation Literature With Verified Citations

Run your own PROTAC, molecular glue, or E3 ligase query on BioSkepsis. Every claim comes with a PMID, a verification badge, and a direct link to the source paper.

Start free

Sources & further reading

1. PMID: 11438690 — Sakamoto et al. (2001). Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation.
2. PMID: 25999370 — Winter et al. (2015). Phthalimide conjugation as a strategy for in vivo target protein degradation.
3. PMID: 26075522 — Lu et al. (2015). Hijacking the E3 ubiquitin ligase Cereblon to efficiently target BRD4.
4. PMID: 31792461 — Khan et al. (2019). A selective BCL-X_L PROTAC degrader achieves safe and potent antitumor activity.
5. PMID: 32728216 — Banik et al. (2020). Lysosome-targeting chimeras for degradation of extracellular proteins.
6. PMID: 33197925 — Hansen et al. (2020). CC-90009: A Cereblon E3 ligase modulating drug that promotes selective degradation of GSPT1.
7. PMID: 35042991 — Bekes et al. (2022). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery.
8. PMID: 36041010 — Ottis et al. (2022). Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway.
9. PMID: 36046485 — Bricelj et al. (2022). E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points.
10. PMID: 37437222 — Molecular glue degraders: rational discovery and design. Cell Chemical Biology.
11. PMID: 37443112 — Ternary complex cooperativity as a predictor of PROTAC degradation potency.
12. PMID: 38322348 — Mutations in E3 ligase components and resistance to targeted protein degradation.
13. PMID: 38685916 — Targeted protein degradation for neurodegenerative diseases: current status and emerging strategies.
14. PMID: 38724444 — Protein half-life and resynthesis rate as determinants of degrader efficacy.
15. PMID: 39585895 — ERD-12310A: a potent ERα degrader with picomolar DC₅₀ and in vivo ESR1 mutant activity.
16. PMID: 39670468 — Bavdegalutamide (ARV-110): preclinical evaluation and AR degradation at 1 nmol/L DC₅₀.
17. PMID: 39759140 — CELMoDs and molecular glues in clinical development for haematological malignancies.
18. PMID: 40045307 — NX-5948 (BTK degrader) clinical data in autoimmune and B-cell malignancy indications.
19. PMID: 40109019 — Autophagy-targeting chimeras (AUTOTACs) and pepTACs for aggregate-prone neurodegenerative targets.
20. PMID: 40266852 — Event-driven pharmacology and the expanding scope of the degradable proteome.
21. PMID: 40284496 — Nanoparticle-based delivery systems for overcoming PROTAC pharmacokinetic liabilities.
22. PMID: 40324952 — LYTACs and extracellular protein degradation: mechanisms and preclinical progress.
23. PMID: 41362117 — Targeted protein degradation: mechanisms, milestones, and resistance. Annual Review of Pharmacology.
24. PMID: 41683435 — Molecular glue resistance mechanisms: CRBN mutations, neo-substrate interface disruption, and alternative E3 ligase strategies.